Applied Biosystems Japan Announces Establishment of Science Center Japan
Applied Biosystems Japan Ltd. (ABJ), a division of the Applied Biosystems Group (NYSE:ABI) of Applera Corporation, announced the establishment of Science Center Japan to develop and promote scientific collaborations between Japanese researchers and business partners in life science research. ABJ intends to strengthen its support of the local research and development community through the creation of this new entity. The announcement was made yesterday at a press conference in Tokyo, Japan.
Science Center Japan plans to invest Applied Biosystems’ and ABJ’s cooperative resources such as personnel, equipment, financial resources, and information for the benefit of Japanese researchers and business partners. A significant team of Applied Biosystems application specialists will also collaborate with outside organizations and share information between these organizations for internal research and development.
“The establishment of Science Center Japan demonstrates our commitment to the Japanese market,” said Dennis A. Gilbert, Ph.D., Chief Scientific Officer, Applied Biosystems. “We believe this new center will enable ABJ to provide the most appropriate products, technology, and services to meet our customers’ future needs.”
“By building relationships with our customers and encouraging cooperative efforts, Applied Biosystems’ intends to expand research and technology in fields where Japan is already leading,” added Masahide Habu, President of Applied Biosystems Japan. “ABJ has been involved in collaborations both in the research and in business, and going forward we will make additional efforts in these areas. Supporting activities will be performed in a manner that allows ABJ to positively impact the customers in the Japanese market.”
About Applera Corporation and Applied Biosystems
Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of nearly $1.8 billion during fiscal 2005. The Celera Genomics Group (NYSE:CRA) is engaged principally in the discovery and development of targeted therapeutics for cancer, autoimmune and inflammatory diseases. Celera Genomics is leveraging its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop small molecule therapeutics. It is also seeking to advance therapeutic antibody and selected small molecule drug programs in collaboration with global technology and market leaders. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com, or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com/.
Applied Biosystems Forward Looking Statements
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as “believe” among others. These forward-looking statements are based on Applera Corporation’s current expectations. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for such forward-looking statements. In order to comply with the terms of the safe harbor, Applera Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These factors include but are not limited to (1) sales dependent on customers’ capital spending policies and government-sponsored research; and (2) other factors that might be described from time to time in Applera Corporation’s filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Applera does not undertake any duty to update this information, including any forward-looking statements, unless required by law. www.appliedbiosystems.com
Copyright© 2005. Applera Corporation. All rights reserved. Applied Biosystems and Celera are registered trademarks and Applera and Celera Genomics trademarks of Applera Corporation or its subsidiaries in the U.S. and/or certain other countries.
